Michael Bennett: Unfiltered

Capri Loans' OpenAI deal is more than a tech upgrade; it's a bold vision to create an 'AI-native' lender. But can it balance innovation with responsibility?

Autism care provider BlueSprig made TIME's new 'Best Private Companies' list. The real story is how it reveals a new metric for success beyond profit.

With federal-grade security clearance, Judi Health aims to replace the government's tangled legacy systems with a single platform for millions of beneficiaries.

A new wave of 'pooled' retirement plans promises relief for overburdened nonprofits. But is outsourcing fiduciary duty a silver bullet or a new risk?

The era of 'buy the software, good luck' is over. Netcore.ai's rebrand isn't just about AI; it's a radical bet on shared outcomes. Is this the future of MarTech?

A breakthrough in memory from Innodisk promises a 60% speed boost, tackling the bottleneck that slows AI and setting the stage for next-gen computing.

Knight Therapeutics set a high bar in Q1. As it preps its Q2 results, we look at the strategy and market forces that will define its next chapter.

Anterix's upcoming earnings report isn't just for investors. It's a crucial look at the hidden infrastructure powering our AI, EV, and climate-resilient future.

Antero Midstream posts record operational growth and a key legal win, yet its stock stumbles. A deep dive into the numbers reveals a complex strategy.

Alexander’s, Inc. maintains its hefty $4.50 dividend, but a closer look reveals a risky payout that may not be covered by its core NYC real estate earnings.

G Mining Ventures acquires G2 Goldfields, creating a tier-one gold complex in Guyana and spinning off a new exploration firm. A masterclass in M&A.

A single IV shot to halt Parkinson's? Shape Therapeutics' radical RNA-editing therapy, now backed by The Michael J. Fox Foundation, aims to do just that.

Beyond record profits, GD's latest report reveals surging demand in private jets and naval power, signaling key shifts in the 2026 global economy.

Facing delisting and declining revenue, STRATA taps a commercial expert to turn reimbursement codes into a growth story. It's a high-stakes MedTech pivot.

The North Bay bank took a deliberate $1.3M loss to purge bad loans. Is this a shrewd move for future strength or a sign of deeper trouble in the local economy?

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.

Pentair's acquisition of Taco Group Holdings is more than a financial transaction; it's a calculated move into the high-growth heart of sustainable infrastructure.

In a world where downtime costs millions, Sunlight Batteries USA's new Quick Ship Program promises a 24-hour fix. Is this the future of supply chain resilience?

After two decades in biosecure labs, Panama's iconic golden frog is back outdoors. Can innovative science and a global coalition defeat a deadly fungus?

With 72% annual turnover costing restaurants billions, a new platform offers every worker a free AI agent. Is this the future or just high-tech churn management?